Liothyronine Sodium tablets recalled due to failed impurity and degradation specifications
Sun Pharmaceutical is recalling 96,192 bottles of Liothyronine Sodium Tablets nationwide due to failed quality specifications for impurities and degradation. The affected lots were distributed in 100-count bottles.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The recall is based on failed quality control specifications (impurities and degradation), classified as a precautionary measure.
Plain-English summary
Sun Pharmaceutical Industries Inc. is recalling 96,192 bottles of Liothyronine Sodium Tablets, USP 5 mcg, nationwide. The recall affects lot numbers DND0059A through DND0184A with expiration dates ranging from December 2023 through February 2024.
The tablets were recalled because they failed to meet quality specifications for impurities and degradation. The product was manufactured by Sun Pharmaceutical Industries Ltd. in India and distributed by Sun Pharmaceutical Industries Inc. located in Cranbury, New Jersey.
The recalled product
- Product
- LIOTHYRONINE SODIUM (LIOTHYRONINE SODIUM)
- Brand
- LIOTHYRONINE SODIUM
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Hazard
- impurities
- degradation
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LIOTHYRONINE SODIUM
- HighLiothyronine Sodium Tablets Recalled for Failed Impurity and Degradation Specifications
FDA (Drugs) · 2023-11-08
- HighLiothyronine Sodium Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2023-11-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27